Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial

Autor: Birring, Surinder S, Cardozo, Linda ^*, Dmochowski, Roger, Dicpinigaitis, Peter, Afzal, Amna, La Rosa, Carmen, Lu, Susan, Nguyen, Allison Martin, Yao, Ruji, Reyfman, Paul A ^*

Publikováno v: In The Lancet Respiratory Medicine November 2024 12(11):855-864

The proteostatic network chaperome is downregulated in F508del homozygote cystic fibrosis

Autor: Sala, Marc A., Alexander, Michael, Khuder, Basil, Politanska, Yuliya, Abdala-Valencia, Hiam, Budinger, G.R. Scott, Liu, Jing, Jain, Manu, Reyfman, Paul A.

Publikováno v: In Journal of Cystic Fibrosis March 2021 20(2):356-363

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough

Autor: McGarvey, Lorcan, Sher, Mandel, Shvarts, Yury Grigorievich, Lu, Susan, Wu, Wen-Chi, Xu, Ping, Schelfhout, Jonathan, La Rosa, Carmen, Nguyen, Allison Martin, Reyfman, Paul A., Afzal, Amna Sadaf

Publikováno v: McGarvey, L, Sher, M, Shvarts, Y G, Lu, S, Wu, W-C, Xu, P, Schelfhout, J, La Rosa, C, Nguyen, A M, Reyfman, P A & Afzal, A S 2023, ' The efficacy and safety of gefapixant in a phase 3b trial of patients with recent-onset chronic cough ', Lung . https://doi.org/10.1007/s00408-023-00606-w

Purpose We evaluated gefapixant, a P2X3 receptor antagonist, in participants with recent-onset (≤ 12 months) refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods Participants (≥ 18 years of age; ≥ 40 mm on a 100-mm cough s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe4b31f8dafcc1e8fcf28110c8f97217
https://doi.org/10.1007/s00408-023-00606-w

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.